Essex Woodlands Healthcare Partners

Cardiva Medical, Inc. is a medical device company that specializes in vascular access management products aimed at facilitating the body's natural healing process after percutaneous catheterization procedures. Its product lineup includes VASCADE VCS, a bioabsorbable femoral access closure system that promotes rapid hemostasis and reduces complications. Additionally, Cardiva offers the Catalyst manual compression assistance device, which supports temporary hemostasis and improves coagulation for patients needing manual compression. The company also manufactures VASCADE MVP, a vascular closure system for multi-site venous closure during electrophysiology procedures such as cardiac ablation. Founded in 2002 and headquartered in Santa Clara, California, Cardiva Medical serves physicians and cardiac centers across the United States.

TissueTech, Inc. specializes in developing regenerative products derived from human amniotic and umbilical cord tissues for applications in ophthalmology, optometry, musculoskeletal care, and wound management. The company offers cryopreserved amniotic membranes and umbilical cord products, utilizing proprietary technologies such as CryoTek, which preserves the biological integrity of placental tissues, and SteriTek, which ensures shelf stability while maintaining natural hydration. Founded in 1997 and based in Miami, Florida, TissueTech focuses on providing enhanced regenerative healing solutions that allow physicians to improve patient outcomes in various medical fields.

Xenex is a company focused on reducing healthcare-associated infections (HAIs) through its advanced ultraviolet disinfection technology. Founded in 2009 and based in San Antonio, Texas, Xenex has developed a portable device that utilizes pulsed xenon UV light to eliminate harmful microorganisms in hospital environments. Since launching its disinfection system in June 2010, the company’s devices have been integrated into infection control protocols in nearly three hundred hospitals across the United States. By effectively reducing the bacterial load that contributes to HAIs, Xenex aims to enhance patient safety and safeguard healthcare staff, ultimately striving to save lives and alleviate suffering in healthcare settings.

Prolacta Bioscience Inc. specializes in developing and producing human milk-based nutritional products tailored for premature and critically ill infants in neonatal intensive care units (NICUs). Founded in 1999 and headquartered in Duarte, California, the company offers a range of products including human milk fortifiers, caloric fortifiers, standardized human milk, and ready-to-feed formulas. Prolacta is notable for being the first company to provide a human milk fortifier made entirely from human milk, known as Prolact+ H2MF. The company operates a pharmaceutical-grade processing facility that employs patented methods to ensure the quality and safety of its products, which address the immunological and nutritional needs of vulnerable infants. Prolacta Bioscience is committed to enhancing the quality of life for critically ill infants through innovative research and specialized formulations.

Metabolon is a technology company, develops analytical methods and software for biomarker discovery using metabolomics. It offers a biochemical profiling platform that analyzes and identifies biochemicals in the research of pharmaceutical, biotech, agriculture, cosmetic, and consumer products. Metabolon provides a unique, real-time fingerprint of biological system to reveal novel discoveries and realize the promise of precision medicine. The company can deliver an instantaneous snapshot of the entire physiology of a living being at a discreet point in time, as well as identify changes in that system brought about the impact of the disease, medical intervention, diet, or the environment. This deep and comprehensive view of the metabolome provides biological insights that cannot be revealed through any other research methodology, enabling life sciences researchers and drug developers to discover answers to some of biology’s most difficult questions. Metabolon was founded in 2000 and headquartered in Durham, North Carolina.

Suneva Medical, Inc. is a medical technology company that develops, manufactures, and commercializes innovative aesthetic products for the dermatology, plastic, and cosmetic surgery markets. Based in San Diego, California, the company offers a range of products, including Bellafill, a unique dermal filler recognized for its long-term safety and efficacy, specifically approved for the correction of facial acne scars and moderate to severe nasolabial folds. Additionally, Suneva Medical provides Puregraft, which enhances fat graft retention, and Suneva Medical HD platelet-rich plasma, facilitating optimal platelet concentrate processing. The company also markets Silhouette InstaLift sutures for cosmetic facial procedures. With a focus on high patient satisfaction and distinct product offerings, Suneva Medical aims to meet the needs of both physicians and patients in the aesthetic market.

TearScience, Inc. is a medical device company that engages in identifying, diagnosing, and treating meibomian gland disease (MGD), which is the cause of dry eye. The company focuses on the early detection and treatment of prevalent, chronic, and progressive MGD. It develops LipiFlow Activator, a single-use sterile device that delivers automated therapeutic energies to each meibomian gland while protecting the delicate structures of the patient’s eye; and LipiScan, a gland imager that allows eye care professionals to evaluate meibomian glands in practices. The company was formerly known as Kolis Scientific, Inc. and changed its name to TearScience, Inc. in July 2005. TearScience, Inc. was founded in 2005 and is based in Morrisville, North Carolina. As of September 6, 2017, TearScience, Inc. operates as a subsidiary of Johnson & Johnson Surgical Vision, Inc.

Kona Medical, Inc. is a medical technology company based in Issaquah, Washington, founded in 2009 by Dr. Michael Gertner. The company specializes in developing a non-invasive ultrasound-based therapy system aimed at treating hypertension and related disorders. Its primary product, Surround Sound, is a hypertension therapy system that employs ultrasound imaging to precisely deliver focused ultrasound energy for renal denervation. This innovative approach targets the nerves associated with kidney function, offering a less invasive alternative for patients suffering from drug-resistant hypertension. By leveraging advancements in therapeutic focused ultrasound, Kona Medical seeks to improve treatment efficacy and reduce the health risks associated with high blood pressure.

AxoGen, Inc. engages in the development of treatment options for the repair of peripheral nerve injuries. It offers AVANCE Nerve Graft, a human allograft nerve that is used for the repair, replacement, and reconstruction of damaged peripheral nerves. The company accepts orders through phone, fax, or email. It serves surgeons. AxoGen has a strategic tissue recovery partnership with American Tissue Services Foundation (ATSF). The company was founded in 2002 and is based in Alachua, Florida.

QSpex Technologies, Inc., an optical service center, offers finished eyewear in the United States. It offers high impact, single vision, progressive, anti reflective, photochromic, and polar lenses. The company was founded in 2007 and is based in Alpharetta, Georgia. On June 8, 2020, QSpex Technologies, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

PreCision Dermatology is a fully-integrated dermatology company with a mission to deliver innovative therapies to doctors and patients that demonstrably improve the care of skin. PreCision Dermatology is expanding rapidly through internally generated innovation, acquisitions, in-licensing, and co-marketing opportunities.

Revance Therapeutics, Inc. is a biotechnology company focused on the development, manufacture, and commercialization of neuromodulators for aesthetic and therapeutic uses. The company’s lead product, DaxibotulinumtoxinA for injection (DAXI), is undergoing clinical trials for various conditions, including glabellar lines, cervical dystonia, adult upper limb spasticity, and chronic migraine. In addition, DAXI is being evaluated for cosmetic applications such as forehead lines and lateral canthal lines. Revance is also developing DaxibotulinumtoxinA Topical for both therapeutic and aesthetic purposes, and it is working on a biosimilar to BOTOX in collaboration with Mylan. Founded in 1999 and originally known as Essentia Biosystems, the company is headquartered in Newark, California.

Catalyst Biosciences is a clinical-stage biopharmaceutical company based in South San Francisco, California, specializing in the development of innovative treatments for hemophilia and other rare bleeding disorders. The company focuses on engineered subcutaneous coagulation factors that enhance blood clotting, aiming to improve patient outcomes compared to traditional intravenous treatments. Its key products include Marzeptacog alfa (activated), an advanced coagulation Factor VIIa that has completed Phase II trials for patients with hemophilia A or B with inhibitors, and Dalcinonacog alfa, an engineered Factor IX therapy that has finished Phase IIb clinical trials for hemophilia B. Catalyst is also developing early-stage gene therapy constructs and long-acting anti-C3 proteases for conditions such as dry age-related macular degeneration (AMD). The company collaborates with Mosaic Biosciences to create anti-complement factor 3 products for retinal diseases and has a partnership with Biogen for the commercialization of pegylated anti-C3 protease therapies. Founded in 2002, Catalyst Biosciences is dedicated to establishing protease therapeutics as a significant new therapeutic platform.

Yantai Beacon Medical Technology Co., Ltd., founded in 2012 and headquartered in Yantai, China, specializes in the manufacture of medical equipment, notably medical gas systems and oxygen supply systems. The company also offers purification engineering services. Originally established in 1999 as Yantai Beacon Group Company Limited, it operates as a subsidiary of Bright Future (Hong Kong) Holding Ltd. Through its innovative solutions, Yantai Beacon Medical aims to enhance healthcare delivery by providing essential medical technologies.

Kona Medical, Inc. is a medical technology company based in Issaquah, Washington, founded in 2009 by Dr. Michael Gertner. The company specializes in developing a non-invasive ultrasound-based therapy system aimed at treating hypertension and related disorders. Its primary product, Surround Sound, is a hypertension therapy system that employs ultrasound imaging to precisely deliver focused ultrasound energy for renal denervation. This innovative approach targets the nerves associated with kidney function, offering a less invasive alternative for patients suffering from drug-resistant hypertension. By leveraging advancements in therapeutic focused ultrasound, Kona Medical seeks to improve treatment efficacy and reduce the health risks associated with high blood pressure.

BreatheAmerica provides treatment facilities for patients suffering from breathing and other related allergic problems. BreatheAmerica is a company dedicated to improving how healthcare services are delivered to patients who suffer from chronic airway diseases - allergy, sinusitis, asthma, and other related diseases - with the goal of improving outcomes, reducing healthcare expenditures, and delivering an exceptional, differentiated patient experience. Joseph C. Hutts and Derril Reeves formed the company in Nashville, Tennesee in 2006.

Catalyst Biosciences is a clinical-stage biopharmaceutical company based in South San Francisco, California, specializing in the development of innovative treatments for hemophilia and other rare bleeding disorders. The company focuses on engineered subcutaneous coagulation factors that enhance blood clotting, aiming to improve patient outcomes compared to traditional intravenous treatments. Its key products include Marzeptacog alfa (activated), an advanced coagulation Factor VIIa that has completed Phase II trials for patients with hemophilia A or B with inhibitors, and Dalcinonacog alfa, an engineered Factor IX therapy that has finished Phase IIb clinical trials for hemophilia B. Catalyst is also developing early-stage gene therapy constructs and long-acting anti-C3 proteases for conditions such as dry age-related macular degeneration (AMD). The company collaborates with Mosaic Biosciences to create anti-complement factor 3 products for retinal diseases and has a partnership with Biogen for the commercialization of pegylated anti-C3 protease therapies. Founded in 2002, Catalyst Biosciences is dedicated to establishing protease therapeutics as a significant new therapeutic platform.

QSpex Technologies, Inc., an optical service center, offers finished eyewear in the United States. It offers high impact, single vision, progressive, anti reflective, photochromic, and polar lenses. The company was founded in 2007 and is based in Alpharetta, Georgia. On June 8, 2020, QSpex Technologies, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

Kona Medical, Inc. is a medical technology company based in Issaquah, Washington, founded in 2009 by Dr. Michael Gertner. The company specializes in developing a non-invasive ultrasound-based therapy system aimed at treating hypertension and related disorders. Its primary product, Surround Sound, is a hypertension therapy system that employs ultrasound imaging to precisely deliver focused ultrasound energy for renal denervation. This innovative approach targets the nerves associated with kidney function, offering a less invasive alternative for patients suffering from drug-resistant hypertension. By leveraging advancements in therapeutic focused ultrasound, Kona Medical seeks to improve treatment efficacy and reduce the health risks associated with high blood pressure.

NeoVista Inc is focused on developing medical technologies aimed at improving the treatment of wet age-related macular degeneration (AMD), a condition that affects over 5 million people globally and is a leading cause of blindness among individuals over the age of 50. The company is engaged in clinical studies to validate its innovative technology, which shows promise in enhancing patient care and alleviating the challenges posed by this debilitating condition for both patients and healthcare providers. Through its efforts, NeoVista aims to significantly impact the quality of life for those affected by wet AMD.

Bioventus LLC develops and/or markets orthobiologic solutions for bone fusion and osteoarthritis. Its active healing therapies product line supports accelerated and more complete healing of bone fractures, and treats the chronic pain associated with osteoarthritis; and bone healing solutions work to enhance the body’s natural healing process. The company also provides injection therapies that treat osteoarthritic joints relieve pain and help bring mobility back to the patient; and surgical orthobiologics. Its products are available through a network of distributors. The company was incorporated in 2011 and is based in Durham, North Carolina. Bioventus LLC operates as a subsidiary of Bioventus Inc.

IntegenX Inc. specializes in developing human DNA identification solutions, utilizing advanced fluidics, optics, and biochemistry to create automated systems for DNA-based human identity testing. The company’s flagship product, the RapidHIT System, provides a sample-to-answer solution for STR-based human identification, generating standardized DNA profiles from buccal swabs and other samples. Additionally, IntegenX offers the RapidHIT GlobalFiler Express Kit for processing various swab types and crime scene samples, as well as RapidHIT PowerPlex 16 HS kits. The company distributes its products through various international channels, including markets in Europe and Asia. Founded in 2003 and based in Pleasanton, California, IntegenX was previously known as Microchip Biotechnologies, Inc. and rebranded in 2010. As of 2018, it operates as a subsidiary of Thermo Fisher Scientific Inc.

Grupo Biotoscana is a prominent biopharmaceutical company based in Montevideo, Uruguay, focused on addressing unmet medical needs in Latin America. Established through the merger of two specialty pharmaceutical companies, it has over 25 years of experience in the industry. The company develops, manufactures, and commercializes a range of medicines targeting various therapeutic areas, including oncology, onco-hematology, infectious diseases, immunology, inflammation, and rare diseases. In addition to its manufacturing capabilities, Grupo Biotoscana engages in the distribution and trade of pharmaceuticals and related products. The company is known for its partnerships with leading global pharmaceutical firms, enhancing its ability to deliver complex treatments and innovative solutions to patients.

BreatheAmerica provides treatment facilities for patients suffering from breathing and other related allergic problems. BreatheAmerica is a company dedicated to improving how healthcare services are delivered to patients who suffer from chronic airway diseases - allergy, sinusitis, asthma, and other related diseases - with the goal of improving outcomes, reducing healthcare expenditures, and delivering an exceptional, differentiated patient experience. Joseph C. Hutts and Derril Reeves formed the company in Nashville, Tennesee in 2006.

Entellus Medical, operating as Stryker ENT, specializes in developing and marketing minimally invasive products for the treatment of chronic sinusitis, eustachian tube dysfunction, and nasal airway obstruction. The company offers a range of innovative solutions, including the XprESS ENT dilation system, which provides versatility in balloon dilation procedures; the custom-fit XprESS LoProfile; and the LATERA absorbable nasal implant, which supports nasal cartilage. Additionally, Entellus Medical provides various surgical instruments and endoscopic imaging solutions designed to enhance treatment outcomes for ear, nose, and throat physicians and their patients. The FinESS Sinus Treatment is a notable product that allows for effective treatment of chronic rhinosinusitis with minimal invasiveness, typically performed under local anesthesia. Founded in 2006 and headquartered in Plymouth, Minnesota, Entellus Medical collaborates with researchers and clinicians to address the specific needs of patients and healthcare providers. The company operates as a subsidiary of Stryker Corporation.

Revance Therapeutics, Inc. is a biotechnology company focused on the development, manufacture, and commercialization of neuromodulators for aesthetic and therapeutic uses. The company’s lead product, DaxibotulinumtoxinA for injection (DAXI), is undergoing clinical trials for various conditions, including glabellar lines, cervical dystonia, adult upper limb spasticity, and chronic migraine. In addition, DAXI is being evaluated for cosmetic applications such as forehead lines and lateral canthal lines. Revance is also developing DaxibotulinumtoxinA Topical for both therapeutic and aesthetic purposes, and it is working on a biosimilar to BOTOX in collaboration with Mylan. Founded in 1999 and originally known as Essentia Biosystems, the company is headquartered in Newark, California.

NeoVista Inc is focused on developing medical technologies aimed at improving the treatment of wet age-related macular degeneration (AMD), a condition that affects over 5 million people globally and is a leading cause of blindness among individuals over the age of 50. The company is engaged in clinical studies to validate its innovative technology, which shows promise in enhancing patient care and alleviating the challenges posed by this debilitating condition for both patients and healthcare providers. Through its efforts, NeoVista aims to significantly impact the quality of life for those affected by wet AMD.

Symphogen A/S is a clinical late-stage biopharmaceutical company based in Ballerup, Denmark, with an additional operation in Somerville, New Jersey. The company specializes in the development of innovative therapies for cancer and other significant diseases, focusing on recombinant polyclonal antibodies. Its pipeline includes several promising candidates, such as Sym004, a mixture of two monoclonal antibodies targeting different epitopes of EGFR, and Sym013, designed to inhibit EGFR, HER2, and HER3 simultaneously. Other notable products in development are Sym015, which targets the MET receptor, Sym021, a monoclonal antibody that blocks PD1, and Sym009, an antibody conjugated to an antibiotic for treating specific strains of staphylococcus aureus. Symphogen aims to address various epithelial cancer indications, including colorectal, lung, brain, breast, pancreatic, and head and neck cancers, ultimately enhancing treatment efficacy and patient outcomes.

Endologix, Inc. is a medical device company that specializes in the development and manufacturing of minimally invasive treatments for abdominal aortic aneurysms (AAA). The company's product portfolio includes several endovascular aneurysm repair (EVAR) systems, such as the AFX endovascular AAA system, which features a minimally invasive delivery mechanism, and the VELA Proximal Endograft, designed for specific aortic neck anatomies. Additionally, Endologix offers the Ovation abdominal stent graft system and the Nellix endovascular aneurysm sealing (EVAS) system, which effectively seals aneurysms while ensuring adequate blood flow to the legs. The company also provides extensions and accessories to customize and facilitate the delivery of its devices. Endologix markets its products through a direct sales force and a network of third-party distributors and agents. Established in 1992 and based in Irvine, California, Endologix has evolved from its original name, Radiance Medical Systems, Inc., to focus solely on addressing critical aortic-related health issues.

ProteinSimple is part of the Protein Platforms division of Bio-Techne (NASDAQ: TECH). They rethinking protein tools and helping thousands of researchers around the world resolve their protein analysis problems so they can reveal new insight into proteins and their role in disease. Their wide-ranging portfolio of tools includes everything from immunoassay systems that quantify protein expression to systems that probe the structure and purity of protein-based therapeutics.

Accumetrics is a privately-held company based in San Diego, California, specializing in the development, manufacturing, and marketing of the VerifyNow System. This system comprises a comprehensive suite of assays designed for the assessment of platelet function, which is crucial in various medical applications, particularly in cardiovascular care. Founded in 1996, Accumetrics was initially sold to Radiometer in 2000 but was repurchased by its management and investors in 2003. The company continues to focus on providing essential tools for healthcare professionals to improve patient outcomes through effective monitoring of platelet activity.

Complete Genomics is a developer of a DNA sequencing platform that focuses on human genome sequencing and analysis. The company offers high-quality and affordable DNA sequencing services, which facilitate large-scale research into the genetic mechanisms that influence drug responses and complex diseases. By integrating proprietary sequencing technology with advanced informatics and data management software, Complete Genomics provides customers with readily usable data for genome-based research. This combination of innovative technology and a disruptive approach positions the company to significantly impact the field of DNA sequencing.

TearScience, Inc. is a medical device company that engages in identifying, diagnosing, and treating meibomian gland disease (MGD), which is the cause of dry eye. The company focuses on the early detection and treatment of prevalent, chronic, and progressive MGD. It develops LipiFlow Activator, a single-use sterile device that delivers automated therapeutic energies to each meibomian gland while protecting the delicate structures of the patient’s eye; and LipiScan, a gland imager that allows eye care professionals to evaluate meibomian glands in practices. The company was formerly known as Kolis Scientific, Inc. and changed its name to TearScience, Inc. in July 2005. TearScience, Inc. was founded in 2005 and is based in Morrisville, North Carolina. As of September 6, 2017, TearScience, Inc. operates as a subsidiary of Johnson & Johnson Surgical Vision, Inc.

Transforming Health Plan Customer Service

Velcera is a specialty pharmaceutical company with a passion for assuring pets receive the medicines they need to support excellent overall health. At Velcera, they are dedicated to developing innovative, high-quality products for the pet health market. They comply with the highest standards of practice through all phases, from development to manufacturing to marketing.

Revance Therapeutics, Inc. is a biotechnology company focused on the development, manufacture, and commercialization of neuromodulators for aesthetic and therapeutic uses. The company’s lead product, DaxibotulinumtoxinA for injection (DAXI), is undergoing clinical trials for various conditions, including glabellar lines, cervical dystonia, adult upper limb spasticity, and chronic migraine. In addition, DAXI is being evaluated for cosmetic applications such as forehead lines and lateral canthal lines. Revance is also developing DaxibotulinumtoxinA Topical for both therapeutic and aesthetic purposes, and it is working on a biosimilar to BOTOX in collaboration with Mylan. Founded in 1999 and originally known as Essentia Biosystems, the company is headquartered in Newark, California.

Molecular Partners AG is a clinical-stage biopharmaceutical company based in Schlieren, Switzerland, focused on developing innovative therapies for serious diseases. The company is advancing a new class of small protein therapeutics known as DARPin, exemplified by its lead candidate Abicipar, which is undergoing Phase III clinical trials for wet age-related macular degeneration and diabetic macular edema. Other candidates in development include MP0250, aimed at enhancing standard treatments for multiple myeloma, and MP0274, currently in Phase I trials for HER2-positive solid tumors. Additionally, MP0310 is being evaluated in Phase I trials for immuno-oncology applications, while MPO317 and Peptide-MHC are designed to activate immune responses within tumors. Molecular Partners collaborates with notable partners, including Allergan and Amgen, and is engaged in a program to develop anti-COVID-19 therapeutics in partnership with AGC Biologics. Founded in 2004, the company aims to significantly improve disease management through its cutting-edge therapeutic approaches.

Entellus Medical, operating as Stryker ENT, specializes in developing and marketing minimally invasive products for the treatment of chronic sinusitis, eustachian tube dysfunction, and nasal airway obstruction. The company offers a range of innovative solutions, including the XprESS ENT dilation system, which provides versatility in balloon dilation procedures; the custom-fit XprESS LoProfile; and the LATERA absorbable nasal implant, which supports nasal cartilage. Additionally, Entellus Medical provides various surgical instruments and endoscopic imaging solutions designed to enhance treatment outcomes for ear, nose, and throat physicians and their patients. The FinESS Sinus Treatment is a notable product that allows for effective treatment of chronic rhinosinusitis with minimal invasiveness, typically performed under local anesthesia. Founded in 2006 and headquartered in Plymouth, Minnesota, Entellus Medical collaborates with researchers and clinicians to address the specific needs of patients and healthcare providers. The company operates as a subsidiary of Stryker Corporation.

Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that offers developing and commercializing products in women’s healthcare and pain management in the United States.The company was formerly known as Xanodyne Pharmacal, Inc. and changed the name to Xanodyne Pharmaceuticals, Inc. in February, 2004. Xanodyne Pharmaceuticals, Inc. was incorporated in 2000 and is based in Newport, Kentucky.

QSpex Technologies, Inc., an optical service center, offers finished eyewear in the United States. It offers high impact, single vision, progressive, anti reflective, photochromic, and polar lenses. The company was founded in 2007 and is based in Alpharetta, Georgia. On June 8, 2020, QSpex Technologies, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

Accumetrics is a privately-held company based in San Diego, California, specializing in the development, manufacturing, and marketing of the VerifyNow System. This system comprises a comprehensive suite of assays designed for the assessment of platelet function, which is crucial in various medical applications, particularly in cardiovascular care. Founded in 1996, Accumetrics was initially sold to Radiometer in 2000 but was repurchased by its management and investors in 2003. The company continues to focus on providing essential tools for healthcare professionals to improve patient outcomes through effective monitoring of platelet activity.

Complete Genomics is a developer of a DNA sequencing platform that focuses on human genome sequencing and analysis. The company offers high-quality and affordable DNA sequencing services, which facilitate large-scale research into the genetic mechanisms that influence drug responses and complex diseases. By integrating proprietary sequencing technology with advanced informatics and data management software, Complete Genomics provides customers with readily usable data for genome-based research. This combination of innovative technology and a disruptive approach positions the company to significantly impact the field of DNA sequencing.

Oraya Therapeutics focuses on developing noninvasive, robotically controlled treatments for inflammatory and neovascular diseases of the eye. The company is currently testing its first application of the IRay system, which aims to provide innovative solutions for eye-related conditions. By leveraging advanced technology, Oraya Therapeutics seeks to improve patient outcomes and enhance the management of ocular diseases.

Chroma Therapeutics Ltd. is a biotechnology company based in Abingdon, United Kingdom, specializing in the discovery and development of novel small molecule drugs targeting cancer and inflammatory disorders. Founded in 2000, Chroma leverages chromatin biology and innovative cell accumulation techniques to create its product pipeline. Key products include Tosedostat, an oral aminopeptidase inhibitor; CHR-3996, an optimized histone deacetylase inhibitor designed for cancer treatment; and CHR-2845, focused on hematological malignancies. The company is recognized for its systematic assembly of intellectual property in chromatin biology and has established a strong network of academic collaborations to enhance its research and development efforts.

Victory Pharma, Inc. is a specialty pharmaceutical company that acquires, markets and develops prescription pharmaceutical products that treat pain and related conditions. Victory markets these products to health care professionals through an experienced US commercial organization. They also develop novel products that effectively treat pain and minimize side effects commonly associated with widely-used pain therapeutics.

NeoVista Inc is focused on developing medical technologies aimed at improving the treatment of wet age-related macular degeneration (AMD), a condition that affects over 5 million people globally and is a leading cause of blindness among individuals over the age of 50. The company is engaged in clinical studies to validate its innovative technology, which shows promise in enhancing patient care and alleviating the challenges posed by this debilitating condition for both patients and healthcare providers. Through its efforts, NeoVista aims to significantly impact the quality of life for those affected by wet AMD.

Symphogen A/S is a clinical late-stage biopharmaceutical company based in Ballerup, Denmark, with an additional operation in Somerville, New Jersey. The company specializes in the development of innovative therapies for cancer and other significant diseases, focusing on recombinant polyclonal antibodies. Its pipeline includes several promising candidates, such as Sym004, a mixture of two monoclonal antibodies targeting different epitopes of EGFR, and Sym013, designed to inhibit EGFR, HER2, and HER3 simultaneously. Other notable products in development are Sym015, which targets the MET receptor, Sym021, a monoclonal antibody that blocks PD1, and Sym009, an antibody conjugated to an antibiotic for treating specific strains of staphylococcus aureus. Symphogen aims to address various epithelial cancer indications, including colorectal, lung, brain, breast, pancreatic, and head and neck cancers, ultimately enhancing treatment efficacy and patient outcomes.

Catalyst Biosciences is a clinical-stage biopharmaceutical company based in South San Francisco, California, specializing in the development of innovative treatments for hemophilia and other rare bleeding disorders. The company focuses on engineered subcutaneous coagulation factors that enhance blood clotting, aiming to improve patient outcomes compared to traditional intravenous treatments. Its key products include Marzeptacog alfa (activated), an advanced coagulation Factor VIIa that has completed Phase II trials for patients with hemophilia A or B with inhibitors, and Dalcinonacog alfa, an engineered Factor IX therapy that has finished Phase IIb clinical trials for hemophilia B. Catalyst is also developing early-stage gene therapy constructs and long-acting anti-C3 proteases for conditions such as dry age-related macular degeneration (AMD). The company collaborates with Mosaic Biosciences to create anti-complement factor 3 products for retinal diseases and has a partnership with Biogen for the commercialization of pegylated anti-C3 protease therapies. Founded in 2002, Catalyst Biosciences is dedicated to establishing protease therapeutics as a significant new therapeutic platform.

Nellix is a medical device company focused on developing innovative solutions for the treatment of Abdominal Aortic Aneurysms (AAAs) and Thoracic Aortic Aneurysms (TAAs). The company's flagship device features a low-profile delivery system and a unique endograft, which allows for less invasive procedures and expands the range of treatable aneurysms. This technology has the potential to significantly increase the market size for Endovascular Aneurysm Repair (EVAR), which has been growing steadily. Nellix aims to improve patient outcomes by providing effective surgical devices that support blood flow through damaged arteries, thereby addressing a critical need in vascular surgery.

Accumetrics is a privately-held company based in San Diego, California, specializing in the development, manufacturing, and marketing of the VerifyNow System. This system comprises a comprehensive suite of assays designed for the assessment of platelet function, which is crucial in various medical applications, particularly in cardiovascular care. Founded in 1996, Accumetrics was initially sold to Radiometer in 2000 but was repurchased by its management and investors in 2003. The company continues to focus on providing essential tools for healthcare professionals to improve patient outcomes through effective monitoring of platelet activity.

Oraya Therapeutics focuses on developing noninvasive, robotically controlled treatments for inflammatory and neovascular diseases of the eye. The company is currently testing its first application of the IRay system, which aims to provide innovative solutions for eye-related conditions. By leveraging advanced technology, Oraya Therapeutics seeks to improve patient outcomes and enhance the management of ocular diseases.

ATS Medical is a medical device manufacturer specializing in cardiovascular surgery products. ATS is a global company with product sales in more than 40 countries across the globe and superior product performance in more than 80,000 mechanical heart valves implanted to date. The ATS Open Pivot® Heart Valve utilizes a unique design specifically intended to offer advantages to the surgeon and improved quality of life to the patient. Instead of cavities in the hinge area, which is the case in all other bileaflet heart valves, The ATS Open Pivot® Heart Valve has open pivots. This enables the leaflets to pivot on smooth spheres that project gently into the bloodstream. The unique configuration eliminates cavities and stagnant areas where blood may collect and clot. For more information about The ATS Open Pivot® Heart Valve, please visit the expanded discussion for patients, physicians, or investors.

Revance Therapeutics, Inc. is a biotechnology company focused on the development, manufacture, and commercialization of neuromodulators for aesthetic and therapeutic uses. The company’s lead product, DaxibotulinumtoxinA for injection (DAXI), is undergoing clinical trials for various conditions, including glabellar lines, cervical dystonia, adult upper limb spasticity, and chronic migraine. In addition, DAXI is being evaluated for cosmetic applications such as forehead lines and lateral canthal lines. Revance is also developing DaxibotulinumtoxinA Topical for both therapeutic and aesthetic purposes, and it is working on a biosimilar to BOTOX in collaboration with Mylan. Founded in 1999 and originally known as Essentia Biosystems, the company is headquartered in Newark, California.

Corium International, Inc. is a biopharmaceutical company specializing in the development, manufacture, and commercialization of specialty pharmaceutical products that utilize transdermal and transmucosal delivery systems. The company offers several products, including a clonidine transdermal delivery system for hypertension, fentanyl patches for chronic pain management, and Crest Whitestrips for teeth whitening. Its product pipeline features innovative therapies, such as Twirla, a hormonal contraceptive patch, and a transdermal system for severe osteoporosis. Additionally, Corium is developing transdermal systems for Alzheimer's disease, psychiatric disorders, and motion sickness. The company collaborates with various pharmaceutical partners to advance its product offerings. Established in 1995, Corium International is headquartered in Menlo Park, California, and operates with a focus on enhancing therapeutic outcomes through advanced drug delivery technologies.

Orthovita is a spine and orthopedic biosurgery company that manufactures and markets orthobiologic and biosurgery products. Its orthobiologics platform offers products for the fusion, regeneration, and fixation of human bones; and the biosurgery platform provides products for controlling intra-operative bleeding. Orthovita sells its products directly, as well as through non-stocking distributors and independent sales agents in the United States; and directly and through independent stocking distributors internationally. The company has strategic partnerships with Kensey Nash Corporation, Angiotech Pharmaceuticals, and Medafor. It was founded in 1992 and is based in Malvern, Pennsylvania.

Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that offers developing and commercializing products in women’s healthcare and pain management in the United States.The company was formerly known as Xanodyne Pharmacal, Inc. and changed the name to Xanodyne Pharmaceuticals, Inc. in February, 2004. Xanodyne Pharmaceuticals, Inc. was incorporated in 2000 and is based in Newport, Kentucky.

Horizon Therapeutics operates as a biopharmaceutical company. It focuses on the development of prescription drugs for mild to moderate pain relief and arthritis. The company's product candidates include HZT-501, a proprietary fixed-dose combination formulation of NSAID and ibuprofen; and HZT-602, a combination oral drug product consisting of naproxen and famotidine. Horizon Therapeutics is based in Northbrook, Illinois, and was founded in 2005.

Oraya Therapeutics focuses on developing noninvasive, robotically controlled treatments for inflammatory and neovascular diseases of the eye. The company is currently testing its first application of the IRay system, which aims to provide innovative solutions for eye-related conditions. By leveraging advanced technology, Oraya Therapeutics seeks to improve patient outcomes and enhance the management of ocular diseases.

Millennium Pharmacy Systems is a pharmacy services provider to the long-term care industry. Offering a new approach to pharmacy services, Millennium delivers on the promise of "the right drug, for the right patient, at the right time, for the right price" so its customers can deliver the best patient care while reducing costs, and more easily meeting compliance demands. Only Millennium combines Just-In-Time Dispensing with electronic medication and treatment ordering, administration, documentation, and reporting. Millennium backs up the commitment with delivery timeliness and medication accuracy customer guarantees. Millennium is headquartered in Chicago, Illinois.

StrataGent Life Sciences, Inc. is a specialty drug therapy company developing painless, non-invasive versions of therapies that would otherwise be injected. Its products are based on its proprietary microjet technology, which delivers large and small therapeutic molecules without a device penetrating into or through the skin. In May of 2004, StrataGent received a $2 million award from the Advanced Technology Program (ATP) at the National Institute of Standards and Technology to support the development of the StrataGent microjet technology.

EUSA Pharma, established in March 2015 and headquartered in the UK, is a specialty pharmaceutical company with a global presence, particularly in Europe and the USA. The company specializes in oncology and critical diseases, offering a portfolio of five approved specialty hospital products, including Caphosol®, Xenazine®, Collatamp®, Custodiol®, and Fomepizole®. EUSA Pharma focuses on addressing rare diseases and conditions like oral mucositis, a debilitating side effect of cancer treatments, with effective biopharmaceutical solutions. The firm submitted a marketing authorization application for FOTIVDA (tivozanib HCL) as a first-line therapy for renal cell carcinoma in early 2016. EUSA Pharma aims to expand its product offerings through acquisitions and in-licensing, supported by significant funding from prominent life science investors. With direct commercial operations and a distribution network that spans approximately 40 countries, EUSA Pharma is well-positioned to meet the needs of patients worldwide.

Alaunos Therapeutics is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapies aimed at treating heterogeneous solid tumors. The company utilizes innovative platform technologies, including the Sleeping Beauty system, which enables the genetic engineering of immune cells to enhance T-cell functionality for cancer treatment. Alaunos is advancing several therapies, notably Ad-RTS-hIL-12 combined with veledimex, which is currently in Phase 2 trials for recurrent glioblastoma multiforme. Additionally, the company is exploring chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies, leveraging collaborations with renowned institutions such as MD Anderson Cancer Center. The RheoSwitch Therapeutic System is another key technology employed by Alaunos, allowing for precise modulation of gene expression to improve cancer treatment outcomes. Founded in 1998 and based in Boston, Massachusetts, Alaunos is committed to advancing its portfolio of immuno-oncology solutions to address unmet medical needs in cancer care.

Ception Therapeutics is a biopharmaceutical company focused on the discovery and development of novel products to address areas of unmet medical need. Ception was founded by experienced pharmaceutical executives in order to develop and commercialize therapeutics in areas of significant unmet medical need.

Healthcare Brands International (HBI) is a new company helping to turn innovative medical product technology into successful consumer brands.

MicroPort Scientific

Global Cord Blood Corporation operates in the People's Republic of China, specializing in umbilical cord blood storage and related services. The company offers testing, processing, and long-term storage of cord blood for expectant parents, as well as processing and storage of donated cord blood, which is matched with patients in need of transplants. As of March 31, 2020, Global Cord Blood managed three cord blood banks in the Beijing municipality, one in Guangdong province, and another in Zhejiang province. The company, which was previously known as China Cord Blood Corporation, changed its name in March 2018 and is headquartered in Central, Hong Kong. It is a subsidiary of Nanjing Ying Peng Hui Kang Medical Industry Investment Partnership.

NeoVista Inc is focused on developing medical technologies aimed at improving the treatment of wet age-related macular degeneration (AMD), a condition that affects over 5 million people globally and is a leading cause of blindness among individuals over the age of 50. The company is engaged in clinical studies to validate its innovative technology, which shows promise in enhancing patient care and alleviating the challenges posed by this debilitating condition for both patients and healthcare providers. Through its efforts, NeoVista aims to significantly impact the quality of life for those affected by wet AMD.

Prism Pharmaceuticals, Inc., an acute care pharmaceutical company, engages in developing and commercializing cardiovascular injectable products in the United States. Its products include NEXTERONE, an anti arrhythmic agent in the form of injectable amiodarone; and PM103, an intravenous formulation of clopidogrel bisulfate. The company was founded in 2004 and is based in King of Prussia, Pennsylvania.

Chroma Therapeutics Ltd. is a biotechnology company based in Abingdon, United Kingdom, specializing in the discovery and development of novel small molecule drugs targeting cancer and inflammatory disorders. Founded in 2000, Chroma leverages chromatin biology and innovative cell accumulation techniques to create its product pipeline. Key products include Tosedostat, an oral aminopeptidase inhibitor; CHR-3996, an optimized histone deacetylase inhibitor designed for cancer treatment; and CHR-2845, focused on hematological malignancies. The company is recognized for its systematic assembly of intellectual property in chromatin biology and has established a strong network of academic collaborations to enhance its research and development efforts.

Symphogen A/S is a clinical late-stage biopharmaceutical company based in Ballerup, Denmark, with an additional operation in Somerville, New Jersey. The company specializes in the development of innovative therapies for cancer and other significant diseases, focusing on recombinant polyclonal antibodies. Its pipeline includes several promising candidates, such as Sym004, a mixture of two monoclonal antibodies targeting different epitopes of EGFR, and Sym013, designed to inhibit EGFR, HER2, and HER3 simultaneously. Other notable products in development are Sym015, which targets the MET receptor, Sym021, a monoclonal antibody that blocks PD1, and Sym009, an antibody conjugated to an antibiotic for treating specific strains of staphylococcus aureus. Symphogen aims to address various epithelial cancer indications, including colorectal, lung, brain, breast, pancreatic, and head and neck cancers, ultimately enhancing treatment efficacy and patient outcomes.

Touchstone Health, a New York-based Medicare Advantage insurer. Touchstone offers a diverse portfolio of Medicare Advantage product options, including a choice of zero and low dollar co-pay plans with benefits including medical, pharmacy dental and mental health.

Light Sciences Oncology, Inc. develops and manufactures talaporfin sodium for the treatment of tumors and other indications in patients. The company also offers drug activator, an LED based single use disposable device that provides a fixed light dose. Its drug is used for the treatment of patients with hepatocellular carcinoma, metastatic colorectal cancer, and benign prostatic hyperplasia and enlargement of the prostate. The company was founded in 1994 and is based in Bellevue, Washington.

Light Sciences Oncology, Inc. develops and manufactures talaporfin sodium for the treatment of tumors and other indications in patients. The company also offers drug activator, an LED based single use disposable device that provides a fixed light dose. Its drug is used for the treatment of patients with hepatocellular carcinoma, metastatic colorectal cancer, and benign prostatic hyperplasia and enlargement of the prostate. The company was founded in 1994 and is based in Bellevue, Washington.

Receptor Biologix develops receptor-based biological therapeutics for cancer, inflammatory, and autoimmune diseases. The company is headquartered in Palo Alto, California.

Confluent Surgical develops products to address the need for surgical sealing and post-surgical adhesion prevention applications.The company provides DuraSeal, an adjunct to sutured dural repair during cranial surgeries to provide watertight closure. The company was founded in 1998 and is headquartered in Waltham, Massachusetts.

Bausch Health Companies Inc. is a global specialty pharmaceutical, consumer health, and medical device company headquartered in Laval, Canada. The company develops, manufactures, and markets a diverse range of products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. Bausch Health operates through four main segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment focuses on vision care, surgical, and consumer ophthalmology products, while Salix specializes in gastroenterology. Ortho Dermatologics offers dermatological products, and the Diversified Products segment includes pharmaceuticals in neurology and other therapeutic areas. Bausch Health is recognized as a leader in consumer vision care in markets such as India and China and ranks among the top vision care companies in the United States. The company was previously known as Valeant Pharmaceuticals International, Inc. before rebranding in July 2018.

Dow Pharmaceutical Sciences, Inc. engages in the development of topical drug products for pharmaceutical and biotechnology clients.

Symphogen A/S is a clinical late-stage biopharmaceutical company based in Ballerup, Denmark, with an additional operation in Somerville, New Jersey. The company specializes in the development of innovative therapies for cancer and other significant diseases, focusing on recombinant polyclonal antibodies. Its pipeline includes several promising candidates, such as Sym004, a mixture of two monoclonal antibodies targeting different epitopes of EGFR, and Sym013, designed to inhibit EGFR, HER2, and HER3 simultaneously. Other notable products in development are Sym015, which targets the MET receptor, Sym021, a monoclonal antibody that blocks PD1, and Sym009, an antibody conjugated to an antibiotic for treating specific strains of staphylococcus aureus. Symphogen aims to address various epithelial cancer indications, including colorectal, lung, brain, breast, pancreatic, and head and neck cancers, ultimately enhancing treatment efficacy and patient outcomes.

LipoSonix, Inc. operates as a medical device company. The company develops non-invasive body sculpting products for aesthetic applications. The company was founded in 1999 and is based in Bothell, Washington. As of July 1, 2008, LipoSonix, Inc. operates as a subsidiary of Medicis Pharmaceutical Corp.

Accumetrics is a privately-held company based in San Diego, California, specializing in the development, manufacturing, and marketing of the VerifyNow System. This system comprises a comprehensive suite of assays designed for the assessment of platelet function, which is crucial in various medical applications, particularly in cardiovascular care. Founded in 1996, Accumetrics was initially sold to Radiometer in 2000 but was repurchased by its management and investors in 2003. The company continues to focus on providing essential tools for healthcare professionals to improve patient outcomes through effective monitoring of platelet activity.

Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that offers developing and commercializing products in women’s healthcare and pain management in the United States.The company was formerly known as Xanodyne Pharmacal, Inc. and changed the name to Xanodyne Pharmaceuticals, Inc. in February, 2004. Xanodyne Pharmaceuticals, Inc. was incorporated in 2000 and is based in Newport, Kentucky.

Revance Therapeutics, Inc. is a biotechnology company focused on the development, manufacture, and commercialization of neuromodulators for aesthetic and therapeutic uses. The company’s lead product, DaxibotulinumtoxinA for injection (DAXI), is undergoing clinical trials for various conditions, including glabellar lines, cervical dystonia, adult upper limb spasticity, and chronic migraine. In addition, DAXI is being evaluated for cosmetic applications such as forehead lines and lateral canthal lines. Revance is also developing DaxibotulinumtoxinA Topical for both therapeutic and aesthetic purposes, and it is working on a biosimilar to BOTOX in collaboration with Mylan. Founded in 1999 and originally known as Essentia Biosystems, the company is headquartered in Newark, California.

InSound Medical, Inc. is a privately held company located in Newark, California, specializing in the development and manufacture of advanced hearing solutions. The company is backed by prominent investors such as Johnson & Johnson, DeNovo Ventures, CMEA Ventures, and Psilos Group Managers, LLC. InSound Medical's flagship product is Lyric, an innovative invisible extended wear hearing device designed to provide users with a discreet and effective hearing solution.

BioForm Medical, Inc. is a medical aesthetics company that specializes in developing and commercializing products aimed at enhancing patients' appearances. Its flagship product, RADIESSE, is an injectable dermal filler that provides aesthetic improvements. In addition to RADIESSE, the company offers RADIESSE Voice and RADIESSE Voice Gel for treating vocal fold insufficiency, as well as Coaptite, an injectable implant used to address stress urinary incontinence. BioForm Medical also provides Aethoxysklerol, an injectable agent for varicose vein treatment, and BioGlue, a surgical adhesive for facial aesthetic applications. The company markets its products through sales representatives and third-party distributors targeting dermatologists, plastic surgeons, and other physicians involved in cosmetic procedures across the United States, Europe, and globally.

Rinat Neuroscience, founded in 2001 following a spin-out from Genentech, focuses on developing protein-based therapeutics for various neurological diseases and disorders. The company leverages significant research and development resources previously invested by Genentech to advance its pioneering efforts in antibody drug development. Rinat is dedicated to creating innovative treatments for conditions such as pain, Alzheimer's disease, obesity, diabetes, and neuropathies. Additionally, it is engaged in developing novel therapies aimed at modifying disease progression by targeting and protecting specific populations of neurons affected by these diseases. Through its work, Rinat Neuroscience seeks to improve patient outcomes in the field of neurology.

InSound Medical, Inc. is a privately held company located in Newark, California, specializing in the development and manufacture of advanced hearing solutions. The company is backed by prominent investors such as Johnson & Johnson, DeNovo Ventures, CMEA Ventures, and Psilos Group Managers, LLC. InSound Medical's flagship product is Lyric, an innovative invisible extended wear hearing device designed to provide users with a discreet and effective hearing solution.

Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, enable new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. The company was incorporated in 1997 and is based in Gaithersburg, Maryland. Intercell USA, Inc. was formerly known as Iomai Corporation. As a result of the acquisition of Iomai Corporation by Intercell Ag, Iomai Corporation's name was changed. As of August 5, 2008, Intercell USA, Inc. operates as a subsidiary of Intercell Biomedical Research & Development AG.

LifeCell Corporation develops and markets tissue repair products for various surgical procedures, specializing in reconstructive, urogynecologic, and orthopedic applications. Its product portfolio includes Strattice and AlloDerm regenerative tissue matrixes, used in plastic, reconstructive, general surgical, burn, and periodontal procedures. Additional offerings include Cymetra, a particulate form of AlloDerm suitable for injection; Repliform for urogynecologic surgeries; GraftJacket for orthopedic applications; and AlloCraft DBM for bone grafting. LifeCell products are utilized in a range of medical applications, such as abdominal wall reconstruction, hernia repair, and breast reconstruction. The company distributes its products to patients and healthcare professionals both domestically and internationally. Founded in 1986 and headquartered in Branchburg, New Jersey, LifeCell operates as a subsidiary of Allergan plc.

According to American Heart Association statistics, 20,000-40,000 patients in the United States would benefit from a heart transplant. The MicroMed DeBakey VAD®, jointly developed with Dr. Michael DeBakey, Dr. George Noon and the National Aeronautics and Space Administration (NASA), has the potential to keep many of these people alive until a donor heart becomes available. Weighing less than four ounces, the device is silent and is approximately 1/10 the size of other pulsatile products on the market. The MicroMed DeBakey VAD® is designed to be a lower-cost, less invasive alternative to the commercially available, larger ventricular assist devices (VADs).

Confluent Surgical develops products to address the need for surgical sealing and post-surgical adhesion prevention applications.The company provides DuraSeal, an adjunct to sutured dural repair during cranial surgeries to provide watertight closure. The company was founded in 1998 and is headquartered in Waltham, Massachusetts.

Inhibitex is a clinical-stage biopharmaceutical company dedicated to the development of innovative products that can treat or prevent serious infections. They are applying our expertise in the development of a portfolio of high-value, differentiated infectious disease therapies, each of which has the potential to significantly improve existing standards of care. Their pipeline addresses major viral and bacterial infections, including herpes zoster (shingles), HCV, and S. aureus infections.

Symphogen A/S is a clinical late-stage biopharmaceutical company based in Ballerup, Denmark, with an additional operation in Somerville, New Jersey. The company specializes in the development of innovative therapies for cancer and other significant diseases, focusing on recombinant polyclonal antibodies. Its pipeline includes several promising candidates, such as Sym004, a mixture of two monoclonal antibodies targeting different epitopes of EGFR, and Sym013, designed to inhibit EGFR, HER2, and HER3 simultaneously. Other notable products in development are Sym015, which targets the MET receptor, Sym021, a monoclonal antibody that blocks PD1, and Sym009, an antibody conjugated to an antibiotic for treating specific strains of staphylococcus aureus. Symphogen aims to address various epithelial cancer indications, including colorectal, lung, brain, breast, pancreatic, and head and neck cancers, ultimately enhancing treatment efficacy and patient outcomes.

Spinal Concepts is a biotechnology company focused on spinal fixation products used in the treatment of spinal disorders, diseases, and injuries. The company was founded by Erin McGurk in 1996.

InSound Medical, Inc. is a privately held company located in Newark, California, specializing in the development and manufacture of advanced hearing solutions. The company is backed by prominent investors such as Johnson & Johnson, DeNovo Ventures, CMEA Ventures, and Psilos Group Managers, LLC. InSound Medical's flagship product is Lyric, an innovative invisible extended wear hearing device designed to provide users with a discreet and effective hearing solution.

Since the company’s founding, Cord Blood Registry® (CBR®) has led the industry in technical innovations and provided families with access to current treatments and experimental stem cell therapies for conditions that have no cure. Cord Blood Registry (CBR) is the world’s largest newborn stem cell company. Founded in 1992, CBR is entrusted by parents with storing samples from more than 500,000 children. CBR is dedicated to advancing the clinical application of cord blood and cord tissue stem cells by partnering with institutions to establish FDA-regulated clinical trials for conditions that have no cure today. CBR has helped more than 300 families use their cord blood stem cells for established and experimental medical treatments, more than any other family cord blood bank. CBR’s goal is to expand the potential scope of newborn stem cell therapies that may be available to patients and their families. Cord Blood Registry is headquartered in San Bruno, California. CBR’s owned 80,000 square foot laboratory is located in Tucson, Arizona. Cord Blood Registry is a registered trademark of CBR Systems, Inc. CBR maintains standards for cellular therapy services through AABB accreditation, FDA-registration, and CLIA certification. CBR has the longest history of accreditation with the AABB (formerly known as the American Association of Blood Banks) and the company’s quality standards have been recognized through ISO 9001:2008 certification — the global business standard for quality. A pioneer in newborn stem cell collection and cryopreservation, CBR believes in the power of newborn stem cells to improve lives today and their potential to revolutionize treatment for many conditions in the future. CBR is the first family newborn stem cell bank to partner with leading research institutions to establish FDA-regulated clinical trials exploring the potential regenerative ability of stem cells to help treat conditions that have no cure today, including: acquired hearing loss, autism, cerebral palsy, and pediatric stroke. In fact, 73% of the stem cell units released by CBR have been used for experimental regenerative therapies – more than any other family cord blood bank in the world.

Rinat Neuroscience, founded in 2001 following a spin-out from Genentech, focuses on developing protein-based therapeutics for various neurological diseases and disorders. The company leverages significant research and development resources previously invested by Genentech to advance its pioneering efforts in antibody drug development. Rinat is dedicated to creating innovative treatments for conditions such as pain, Alzheimer's disease, obesity, diabetes, and neuropathies. Additionally, it is engaged in developing novel therapies aimed at modifying disease progression by targeting and protecting specific populations of neurons affected by these diseases. Through its work, Rinat Neuroscience seeks to improve patient outcomes in the field of neurology.

IKnowMed is a healthcare company based in Berkeley, California, focused on enhancing oncology care through its innovative web-based electronic health record (EHR) system, iKnowChart. This platform is designed to manage the complexities of cancer treatment by providing a trusted repository of real-time, point-of-care information. It enables clinicians to capture, analyze, and display critical patient treatment data, thus improving the standard of care during significant medical interactions. The system offers oncology providers universal and secure access to patient charts, enhances documentation processes with integrated billing capture, and includes electronic medication ordering with safety monitoring features. Through its electronic infomediary, iKnowMed fosters valuable interactions among physicians, patients, and pharmaceutical organizations, ultimately benefiting all parties involved in the oncology care continuum.

Healthgrades, based in Denver, Colorado, serves as a leading online resource for detailed information about healthcare providers, including physicians and hospitals. It attracts over one million daily users who seek to search, compare, and connect with healthcare professionals based on critical factors such as experience, hospital quality, and patient satisfaction. As an independent healthcare rating organization, Healthgrades provides quality ratings, profiles, and cost information about hospitals, physicians, nursing homes, and prescription drugs. This comprehensive data empowers consumers to make informed decisions regarding their healthcare options, focusing on the quality of care and overall patient experience.

WholePeople.com Inc. is a diverse e-commerce platform focused on the "Whole Living" sector. It offers a comprehensive range of information and products related to health and wellness, including natural vitamins, supplements, herbs, and body care items. The website features sections dedicated to health and body, food, natural home, travel, and wellness plans approved by physicians. This allows users to access relevant information while also providing the option to purchase various goods online, catering to a global audience interested in holistic health solutions.